The company’s molecular translocation technology uses poorly immunogenic mimetics of certain microbe-derived proteins that efficiently and consistently traffic across the length of the intestinal epithelia. Using recombinant and chemical technologies, we design and construct molecules comprising these translocation elements and therapeutic warheads.
Our uniquely formulated, stable protein constructs transit through the intestinal lumen until they contact the epithelial surface. Upon translocation across the GI epithelia, the constructs can either release therapeutic warheads into systemic circulation, or selectively present the warheads to targets within the local intestinal submucosal/gut-associated lymphatic tissue and hepatic-portal system. This provides privileged access to the vast immune system biology located along the GI tract as well as to a plethora of hepatic-portal targets.
Copyright © APPLIED MOLECULAR TRANSPORT, LLC 2016. All rights reserved.
Topographical structure of TRANSINT molecular fusion